| Line Item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Research and development expenses, net | ||||||||
| General and administrative expenses | ||||||||
| Other expenses (expenses for merger with NLS) | ||||||||
| Operating loss | ||||||||
| Financing income | ||||||||
| Financing expenses related to convertible instruments | ||||||||
| Other financing expenses | ||||||||
| Net financing expenses | ||||||||
| Total loss | ||||||||
| Net loss attributable to common shareholders | ||||||||
| Basic loss per share | ||||||||
| Diluted loss per share |